Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas, Janssen to End JAK Inhibitor Licensing Agreement
December 3, 2014
- Nippon Shinyaku’s Selexipag Filed for European Approval
December 3, 2014
- Otsuka to Buy US Firm Avanir Pharmaceuticals to Fully Enter Neurology Market
December 3, 2014
- Takata Seiyaku Obtains Marketing Authorization Rights for Antihistamine Polaramine from MSD
December 3, 2014
- Kowa Launches Glanatec for Treatment of Glaucoma and Ocular Hypertension
December 3, 2014
- Xtandi Approved for Chemotherapy-Naïve Patients in Europe: Astellas
December 3, 2014
- Takeda’s Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by US FDA
December 3, 2014
- A-zas Looks to Offer E-Detailing App, Big-Data Analyses to More Firms
December 2, 2014
- Pralia Captures Top Spot in GP Market in October “Mind Share” Ranking
December 2, 2014
- Eisai Upgrades China to Independent Region with New Holding Firm
December 2, 2014
- Ferring to Launch Japan’s 1st Progestational Hormone Agent in ART Program on Dec. 5
December 2, 2014
- Eisai Files Lenvatinib for Approval in South Korea
December 2, 2014
- MTPC, Sawai Ink Final Pact on Transfer of Kashima Plant in April
December 2, 2014
- Daiichi Sankyo, UCB to Jointly Commercialize Epilepsy Drug Lacosamide
December 1, 2014
- Nippon Kayaku Rolls Out Remicade Biosimilar
December 1, 2014
- Novartis to Launch Stalevo Combination Tablets on Dec. 8
December 1, 2014
- Takeda to Transform Osaka Plant into Specialty Manufacturing Site for Leuplin
December 1, 2014
- Sandoz Launches Biosimilar of G-CSF Product Gran; Comarkets with Sawai
December 1, 2014
- Mochida Applies for Additional Indication of Social Anxiety Disorder for Lexapro
December 1, 2014
- EPS Gives 400 Workers CDISC Training to Set Itself Apart from Rival CROs
November 28, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…